Study objective: Docetaxel has shown activity in the second-line treatment of non-small cell lung cancer (NSCLC). Phase II studies have suggested that weekly therapy with docetaxel probably has a better toxicity profile than the conventional schedule of once every 3 weeks. Our aim was to evaluate and compare the efficacy of different docetaxel schedules in NSCLC patients who did not respond to previous platinum-based chemotherapy. Setting: National teaching hospital in Taiwan 
S
ystemic chemotherapy plays an important role in the treatment of non-small cell lung cancer (NSCLC) patients with advanced disease. In the past decade, cisplatin-based chemotherapy in combination with new anticancer drugs has become the standard of treatment for chemotherapy-naïve patients with inoperable NSCLC. 1, 2 However, there has been no significant difference in efficacy demonstrated among the different new anticancer drugs, only in their toxicity profiles and cost. 3 In contrast to first-line chemotherapy, in which no specific new anticancer drug has been found to be more effective than other agents, docetaxel is the standard second-line chemotherapeutic agent used against NSCLC. 4 -6 The recommended dose of docetaxel in pretreated NSCLC patients is 75 mg/m 2 For editorial comment see page 840 every 3 weeks. 4 -6 However, a relatively lower dose level is probably adequate for Asian patients, in terms of antitumor activity and drug-induced toxicities, and a dosage of 60 mg/m 2 every 3 weeks has been recommended for Japanese patients. [7] [8] [9] Once docetaxel treatment every 3 weeks has shown activity against NSCLC, investigators began to pay attention to the possibility of a weekly treatment schedule. The results were that weekly docetaxel treatment could reduce treatment-related toxicities while maintaining antitumor activity. 10, 11 Thus, the present study was designed to compare the efficacy of the following three different docetaxel schedules in NSCLC patients who had not responded to previous platinum-based chemotherapy: 35 mg/m 2 IV infusion on days 1, 8, and 15 every 4 weeks (D 35 ); 40 mg/m 2 IV on days 1 and 8 every 3 weeks (D 40 ); and 75 mg/m 2 IV on day 1 every 3 weeks (D 75 ). All three arms of the study had similar intended weekly dose intensities, with the dose intensity of the first arm being slightly higher. In this clinical trial, we hoped to determine whether or not the usually recommended docetaxel dose, 75 mg/m 2 IV on day 1 every 3 weeks, is too toxic to be tolerable for our Chinese patients, and whether weekly treatment is better tolerated than the schedule of every 3 weeks.
Materials and Methods
The study was conducted according to the existing rules for good clinical practice, and the study protocol was approved by the local ethics committee. Patients with NSCLC who had not responded to previous platinum-based chemotherapy, aged Ն 18 years, were entered into the study after giving informed consent. The eligibility criteria were as follows: a histologic or cytologic diagnosis of stage IIIb or IV NSCLC in patients who had not responded to previous platinum-based chemotherapy; a performance status of 0 to 2 on the Zubrod scale; clinically measurable disease, defined as bidimensionally measurable lesions; no previous radiotherapy on measurable lesions; adequate bone marrow reserve with a WBC count of Ն 4,000 cells/L, a platelet count of Ն 100,000 cells/L, and a hemoglobin concentration of Ն 10 g/dL; and no previous history of docetaxel treatment. The exclusion criteria were as follows: inadequate liver function (bilirubin level Ͼ 1.5 times above the normal range, and alanine transferase and aspartate transferase levels more than three times normal); inadequate renal function with a creatinine concentration of Ͼ 2.0 mg/dL; and neurologic conditions that could interfere with the evaluation of neurologic toxicity.
The 12 For dose adjustments to the subsequent cycle, a 20% reduction in docetaxel was instituted when the patient experienced grade 4 neutropenia or febrile neutropenia. A 40% reduction of the full dose was instituted if the patient still experienced grade 4 myelosuppression after a 20% dose reduction. A subsequent dose escalation to the original dose level was allowed, provided that the patient tolerated the doses given at the lower level. For nonhematologic toxicities, docetaxel doses were reduced to 80% if there were grade 3 toxicities, excluding nausea/vomiting and alopecia.
Baseline evaluations included a documentation of the patient's history, a physical examination, and a performance score. A CBC count, serum biochemistry profile, ECG, whole-body bone scan, brain CT scan, and chest (including liver and adrenal glands) CT scan were also performed.
An evaluation of the response was performed in the D 35 arm after the first two courses of chemotherapy and every two courses thereafter, and after the first three courses of chemotherapy and every three courses thereafter in the D 40 and D 75 arms of the study. The types of responses were also assessed according to established Eastern Cooperative Oncology Group criteria. 12 Responding patients and those with stable disease had their treatment continued until disease progression or the completion of a maximum of six courses of chemotherapy in the D 35 45 and D 75 arms. The lung cancer symptom scale score was recorded before every course of chemotherapy and when the patient completed or went off the study. 13 This study was designed to enroll 53 qualified patients into each arm. This calculation assumes that the true response probability for the best treatment would be 10 points better than that for the others. Assume that the smaller treatment response rate was 15% and the higher treatment response rate was 25%, with a power of 0.9 and a p value of 0.05, and that each treatment group requires 53 qualified patients. 14 Since the dosage in the D 75 arm is the usually recommended treatment dose and has been thoroughly studied, and since this arm was used as a control group in the present study, the panel decided to enroll the patients into each arm with a patient ratio of 2:2:1 and a total patient number of at least 159 patients. Eligible patients were randomized into different treatment arms by a statistical office not involved in the trial. The data were collected prospectively.
The response rate and survival analysis were all analyzed with an intention-to-treat principle. Overall survival and the time to disease progression were analyzed using the Kaplan-Meier estimation method. The time to disease progression was calculated from the date of the initiation of treatment to the date of disease progression or death. If disease progression had not occurred by the time of this analysis, progression-free survival was considered to be censored at the time of the last follow-up. Survival time was measured from the date of the initiation of treatment to the date of death. If death had not occurred, survival time was considered censored at the last follow-up. All comparisons of clinical characteristics, response rates, and toxicity incidences were performed by means of the analysis of variance (ANOVA) test. For the statistical analysis of the lung cancer symptom scale score, the Mann-Whitney test was used for a comparison of the two treatment arms, and the Wilcoxon signed ranks test was used for comparison before and after treatment.
Results
Patients' clinical characteristics are shown in Table  1 . There was no statistical difference in the patients' clinical characteristics among the different treatment arms. The mean age of patients was about 64 years, and more than half of the patients had a performance status of 2. All patients had been previously treated with platinum-based combination chemotherapy. In this study, docetaxel was the second-line chemotherapy in 146 patients and was third-line or greater chemotherapy in 15 patients. With the principle of intention-to-treat, all patients were assessable for toxicity profile and treatment response.
We reduced the docetaxel dose in the D 75 arm to 80% in the first cycle, and escalated the dosage to 100% if there were no more than grade 2 leukopenia or nonhematologic toxicities (except nausea/vomiting), because two of the first three patients in this arm experienced dose-limiting toxicities in their first cycle of treatment, including one with febrile neutropenia and the other with grade 3 asthenia lasting for Ͼ 2 weeks. The patient who experienced febrile neutropenia died, irrespective of our intensive treatment, including IV antibiotics and granulocyte- All patients enrolled into the study were eligible for toxicity evaluation. The main toxicities were hematologic (leukopenia and neutropenia), and patients in the D 75 arm experienced a higher frequency of grade 3 or 4 leukopenia (p Ͻ 0.001) and neutropenia (p Ͻ 0.001) than those in the D 35 and D 40 treatment arms (Table 4) . Febrile neutropenia occurred in one, three, and four patients in the D 35 , D 40 , and D 75 treatment arms, respectively; and zero, two, and two of these patients died despite treatment with antibiotics and granulocyte colony-stimulating 40 , and D 75 arms) who completed the baseline lung cancer symptom scale questionnaire, and after two cycles of treatment and/or after going off-study. The results of the completed lung cancer symptom scale questionnaire showed that there was a slight, though significant (p Ͻ 0.001), decrease in the scores for appetite (patient and observer), fatigue (patient and observer), disease severity, activity, and quality of life, when comparing pretreatment scores with those after two cycles of treatment or after the patient had gone off-study. However, there was no difference in the scales among the different treatment arms before treatment, after two cycles of treatment, or when the patients had gone off-study. This held true whether scored by the patients (nine items) or by the observers (six items), and included the categories of loss of appetite, fatigue, cough, dyspnea, hemoptysis, pain, disease severity, daily activity, and quality of life. However, pain was more severe in patients in the D 40 arm compared to those in the D 75 arm after two cycles of treatment (observer, p ϭ 0.044), disease severity and activity was better in the D 40 arm compared to the D 35 arm both before treatment (patients, p ϭ 0.011; observers, p ϭ 0.033) and after two cycles of treatment (patients, p ϭ 0.019; observers, p ϭ 0.032) [ Table 6 ].
Discussion
In phase II trials of NSCLC patients, 15 singleagent docetaxel, 75 or 100 mg/m 2 , produced objective response rates of 14 to 25% in second-line treatment. Two phase III randomized trials 4,5 revealed that single-agent docetaxel provided meaningful survival and clinical benefits in second-line NSCLC treatment, thus, establishing docetaxel as the standard second-line treatment for NSCLC. The dose recommended in this setting is 75 mg/m 2 every 3 weeks. 4 -6 However, a dosage of 60 mg/m 2 every 3 weeks was suggested for Japanese patients after the Japanese cooperative study 7 of single-agent docetaxel treatment in chemotherapy-naive NSCLC patients had been completed. This dosage schedule of 60 mg/m 2 every 3 weeks was able to induce marked myelosuppression with grade 3 or 4 neutropenia in 73% of patients, and febrile neutropenia in 18% of patients, in another Japanese study. 8 Thus, the docetaxel therapy schedule of 75 mg/m 2 every 3 weeks was probably too toxic to be tolerated by our Chinese patients, as well. Hirata et al, 16 in Japan, found that a docetaxel dose of 35 mg/m 2 weekly for 3 consecutive weeks every 4 weeks was less toxic, and had activity comparable with the previously reported 3-week schedule, as in other phase II studies. 10, 11 This difference in tolerance to taxane treatment between east Asian and white populations was also found in paclitaxel treatment. A Japan-Southwest Oncology Group common-arm analysis of paclitaxel- plus-carboplatin treatment showed a significant difference in toxicity profiles and survival between Japanese and American patients. 17 Further pharmacogenomic study is needed. Since weekly docetaxel treatment has been found to be associated with less toxicity, the present study attempted to compare the efficacy of the conventional schedule of 75 mg/m 2 every 3 weeks with the weekly schedule, and to determine whether or not the schedule of 75 mg/m 2 every 3 weeks is too toxic to be tolerated by our patients. Despite the fact that the majority of patients in the D 75 arm of our study needed a decrease in the treatment dose due to treatment-related toxicities, the actual docetaxel dose intensity given to the patients was similar among the D 35 , D 40 , and D 75 treatment arms (22.3, 23.4 , and 20.8, mg/m 2 /wk, respectively). This means that a weekly schedule cannot effectively increase the patient's dose intensity, compared with the schedule of every 3 weeks, and that a dosage of 75 mg/m 2 every 3 weeks is too toxic to be tolerated by our patients.
Since severe docetaxel-induced pneumonitis occurred most frequently in the D 40 treatment arm in the present study (Table 5) , the occurrence of pneumonitis seemed not to be related to the drug's peak concentration in the blood, as in the D 75 treatment arm, and not related to the frequency of the drug injections, because patients in the D 35 treatment arm had the highest injection frequency. It was also reported that weekly treatment with docetaxel (36 mg/m 2 weekly for 6 weeks every 8 weeks) was associated with a low response rate (2.9%), high pulmonary toxicity (20% grade 3 toxicity), and diarrhea (25.7% grade 2 or 3 toxicity). 18 Based on the results of both studies, we should pay more attention to the problem of drug-induced pneumonitis when patients receive weekly docetaxel treatment.
Two other randomized studies of docetaxel were similar to ours. 19, 20 However, one study 19 20 was a phase II study comparing treatment with docetaxel, 75 mg/m 2 on day 1 every 3 weeks, with that of 40 mg/m 2 weekly for 6 of 8 weeks. The preliminary report of the first study 19 (162 patients evaluable) found that the median number of treatment cycles was higher in the conventional every-3-weeks treatment arm than in the weekly arm (4 vs 2 cycles, respectively), which differed from our results. Grade 3 or 4 neutropenia occurred in only 19.4% and 4.1%, respectively, in each arm of their study; these were much lower rates than that in our patients, even though our patients in the 75 mg/m 2 arm had already reduced the first dose to 60 mg/m 2 every 3 weeks. Thus, the dose of docetaxel that is tolerable is quite different between white and Asian patients. [7] [8] [9] 19 Weekly docetaxel treatment appears to be a particularly attractive treatment option due to its lack of severe toxicity. 19, 20 Similar findings were found in our study, including the use of outpatientbased treatment and relatively better safety profiles, except that the initial dose should be reduced if treatment with docetaxel, 75 mg/m 2 every 3 weeks, is given and drug-induced pneumonitis should be kept in mind.
The median survival time of 7.6 months and the 1-year survival rate of 31.6% for all 161 patients in the present study were similar or even better than those of other phase II or III docetaxel single-drug salvage chemotherapy studies. At least 34 of our patients received gefitinib treatment after they did not respond to the presently studied docetaxel treatment. Gefitinib might play a role in prolonging the survival times of east Asian patients after they have failed to respond to docetaxel treatment. 21, 22 The similar median survival times and 1-year survival rates among the different treatment arms (Fig 2) suggests that both the weekly and the conventional every-3-weeks schedule can be administered with good survival results.
In summary, both the weekly and the conventional every-3-weeks schedule of docetaxel treatment is appropriate for salvage chemotherapy in NSCLC patients. However, weekly docetaxel chemotherapy produces a relatively lower toxicity profile, and better compliance and response rates than the conventional every-3-weeks schedule. These effects were more evident in the D 35 arm weekly schedule than in the D 40 arm weekly schedule. In addition, there was no obvious difference in the dose intensity that the patients received and no difference in the patients' quality of life among the different treatment schedules. However, the docetaxel dose in cycle 1 should be reduced if the conventional treatment of 75 mg/m 2 every 3 weeks is given, and the dose can only be escalated if the patient tolerates the initial treatment well. Physicians should be aware of the possibility of a higher frequency of severe interstitial pneumonitis when weekly treatment is given to the patients.
